MOTS-c Liquid Spray · Research brief
MOTS-c Half-Life: What the Literature Reports
Short answer
Type ' mots c half life' into a search bar and numbers come back fast: 20 minutes on one page, three hours on another, a confident 'roughly 30 minutes' repeated across a dozen supplier listings. Chase any of those figures back to a primary source and most of them vanish.
Key takeaways
- No peer-reviewed human pharmacokinetic study has established a MOTS-c half-life, and any precise figure quoted without an assay and citation should be treated as unsourced.
- MOTS-c is a 16-amino-acid peptide of roughly 2 kDa encoded within the mitochondrial 12S rRNA gene, first characterised by Lee, Cohen and colleagues in Cell Metabolism in 2015.
- Unmodified peptides of that molecular weight pass the glomerular filter freely and are cleaved by serum peptidases, which is why the structurally predicted half life of MOTS-c sits in minutes rather than hours.
- Engineered comparators show what protection does: semaglutide reaches roughly 165 hours through C18 fatty diacid albumin binding, while native GLP-1 lasts about 1.5 to 2 minutes.
- Because MOTS-c is endogenously expressed, ELISA cannot separate administered peptide from native peptide, so credible pharmacokinetics requires stable-isotope tracers with LC-MS/MS.
- Plasma clearance and duration of downstream AMPK-linked signalling are separate measurements, and one cannot be inferred from the other.
Type 'mots c half life' into a search bar and numbers come back fast: 20 minutes on one page, three hours on another, a confident 'roughly 30 minutes' repeated across a dozen supplier listings. Chase any of those figures back to a primary source and most of them vanish.
We supply MOTS-c to research laboratories, and this is the question we field more than any other about the compound. Researchers rarely want a number to drop into a spreadsheet. They want to know what the published record genuinely supports, and where it goes quiet.
What is the half life of MOTS-c?
No validated human pharmacokinetic study has established a MOTS-c half life. MOTS-c is a 16-amino-acid mitochondrial-derived peptide of roughly 2 kDa with no albumin-binding modification, and unmodified peptides of that size are typically cleared from plasma within minutes. Any specific figure quoted online should be traced back to its assay and citation before it is used.
The deeper problem with the question is that it treats plasma clearance and biological duration as the same thing. They aren't. A short mots-c half-life in circulation tells you very little about how long AMPK-linked signalling persists inside a cell after exposure. What follows covers what the literature does and doesn't report, the structural reasons this peptide clears so quickly, and why the assay you pick decides the number you get.
What the published record on MOTS-c actually reports
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) was first described by Changhan Lee, Pinchas Cohen and colleagues at the University of Southern California in Cell Metabolism in 2015. It is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene (MT-RNR1), one of a small family of mitochondrial-derived peptides that includes humanin. The reported mechanism runs through the folate-methionine cycle: interference with that pathway drives accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which activates AMPK (AMP-activated protein kinase), the enzyme that shifts cells from storage toward substrate oxidation.
Later work from the same group, published in Nature Communications in 2021, reported that MOTS-c levels rise in skeletal muscle and plasma with exercise in humans. A mitochondrial DNA polymorphism, m.1382A>C, which produces a K14Q MOTS-c variant, has been linked to type 2 diabetes risk in East Asian cohorts in work published in Aging Cell.
Here's the gap. Not one of those papers is a pharmacokinetic study. They are pharmacodynamic and genetic papers. Nobody in that literature set out to report a terminal t1/2, which is exactly why the half life of MOTS-c peptide has no canonical citation. Rodent studies administered the peptide repeatedly rather than relying on prolonged circulating presence, and endogenous plasma concentrations measured by ELISA vary widely between published cohorts.
Our team has read through this body of work repeatedly looking for a clean MOTS-c half-life figure. It isn't there.
Why a 16-amino-acid peptide leaves circulation quickly
The short MOTS-c half-life predicted by structural reasoning comes down to three things acting at once: size, sequence, and the absence of any protective modification.
At roughly 2 kDa, MOTS-c sits far below the glomerular filtration threshold. The kidney filters freely below about 30 to 50 kDa, and albumin at 66.5 kDa is largely retained. A 16-residue peptide passes straight through. Second, unprotected peptide bonds are substrate for serum aminopeptidases and endopeptidases, so proteolytic cleavage begins immediately in plasma. Third, MOTS-c carries no fatty-acid acylation, no PEG chain, and no FcRn-recycling scaffold. Nothing tethers it to albumin and nothing hides it from clearance.
Compare that to semaglutide, which achieves a terminal half-life of roughly 165 hours through a C18 fatty diacid linker that binds albumin plus an AIB substitution that blocks DPP-4 cleavage. Same general class of molecule, wildly different persistence, entirely because of chemistry that MOTS-c does not have.
One mistake shows up constantly, and it isn't a biology error at all. Many of the 'half-life' figures on vendor pages describe solution stability, not plasma pharmacokinetics. A reconstituted vial held at 2 to 8°C and a peptide circulating in blood are two completely different degradation environments, governed by temperature and pH in one case and by peptidases and renal filtration in the other. Conflating them produces numbers that are wrong by orders of magnitude.
Plasma clearance, signalling duration, and why the assay decides the number
Any reported half-life is an artefact of the assay that produced it. Two labs measuring the same MOTS-c exposure with different methods will publish different numbers, and both can be technically correct.
The specific obstacle with this peptide is endogenous background. MOTS-c is expressed constitutively from mitochondrial DNA, so plasma always contains some. An immunoassay cannot distinguish administered peptide from native peptide, which means any apparent MOTS-c half-life derived from ELISA alone is measuring a mixed pool. Clean pharmacokinetics for an endogenous peptide requires a stable-isotope-labelled tracer plus LC-MS/MS quantification with a validated lower limit of detection. Publicly available datasets of that kind for MOTS-c are scarce, and that scarcity, not biological mystery, is why the mots-c half-life in the body remains an open question.
Then there's the decoupling problem. AMPK activation triggers phosphorylation cascades and transcriptional changes, and the USC group has reported MOTS-c translocating to the nucleus under metabolic stress to influence stress-adaptive gene expression. Transcriptional effects can persist long after the peptide itself is undetectable. Plasma t1/2 measures clearance. It does not measure consequence.
On the bench side, lyophilised peptide is generally held at -20°C or colder, reconstituted material refrigerated at 2 to 8°C, and repeated freeze-thaw cycles avoided because each one risks aggregation. This article is research education only. These compounds are supplied for laboratory research, are not FDA-approved drugs, and are not for human or veterinary consumption. Anyone with a question about an animal's health should talk to their veterinarian rather than extrapolating from research literature.
MOTS-c half-life compared with engineered long-acting peptides
The table below puts the MOTS-c half-life question next to peptides where terminal t1/2 has been formally established, because the contrast explains the mechanism better than any single figure can.
| Compound | Reported terminal half-life | Why the number lands where it does | Bottom Line |
|---|---|---|---|
| MOTS-c (16 aa, ~2 kDa, unmodified) | No validated published t1/2; structurally predicted in the minutes range | Below the glomerular filtration cutoff, no albumin binding, freely cleaved by serum peptidases | Treat every specific number circulating online as unsourced until you see the assay and the citation behind it |
| Native GLP-1 (7-36 amide) | Approximately 1.5 to 2 minutes | N-terminal cleavage by DPP-4 begins almost immediately after secretion | The benchmark for how fast an unprotected small peptide disappears from plasma |
| Liraglutide | Approximately 13 hours | C16 palmitic acid linker enabling reversible albumin binding plus self-association at the injection site | Demonstrates what a single fatty-acid modification buys: daily rather than minute-scale exposure |
| Semaglutide | Approximately 165 hours (about 7 days) | C18 fatty diacid with high albumin affinity, plus AIB substitution resisting DPP-4 degradation | The engineered ceiling for peptide persistence; weekly administration follows directly from the chemistry |
| Tirzepatide | Approximately 5 days | C20 fatty diacid attached to a dual GIP and GLP-1 receptor agonist backbone | Confirms that half-life is a design output, not an intrinsic property of peptide class |
| CJC-1295 with DAC vs without DAC | With DAC, reported in the range of days; without DAC, reported in the region of 30 minutes | The Drug Affinity Complex forms a covalent albumin bond; the unmodified fragment has no such anchor | Same core sequence, roughly two orders of magnitude apart in t1/2, which shows modification rather than sequence sets persistence |
What If: MOTS-c Pharmacokinetic Scenarios
What if a supplier lists a specific half-life on the product page?
Ask which study and which assay produced it. Most quoted figures for this compound have no traceable primary source, and a meaningful number requires a named matrix, a stated detection method, and a sampling window. If a vendor cannot supply those three things, the figure is marketing copy rather than pharmacokinetic data. Purity and identity documentation is a different matter entirely, and that is something a supplier absolutely should be able to produce on request.
What if the published literature reports no t1/2 for the peptide being studied?
Measure it in your own model and report the assay alongside the value. For endogenous peptides like MOTS-c, that means a labelled tracer and LC-MS/MS rather than an immunoassay, because a mixed pool of native and administered peptide will distort the terminal phase. Plenty of peptides with decades of pharmacodynamic literature still have no published pharmacokinetic profile, and treating that absence as an unknown rather than a small number is the honest position.
What if the calculated MOTS-c half-life seems too short to explain an observed effect?
Separate the clearance question from the signalling question before assuming an error. AMPK activation initiates phosphorylation cascades and transcriptional responses that can persist well beyond the point where the peptide is detectable, and the reported nuclear translocation of MOTS-c under metabolic stress offers one route for effects to outlast exposure. Short plasma residence and durable cellular response are not contradictory findings.
What if a reconstituted vial has been refrigerated for several weeks?
Treat solution stability as an entirely separate variable from the mots c half life in plasma. Degradation in a vial is driven by temperature, pH, repeated freeze-thaw cycles and container interactions, not by peptidases or renal clearance. Documenting reconstitution date, storage temperature and handling in the lab record is the only way to interpret a result that drifts from expectation.
The Unsatisfying Truth About Published Half-Life Figures
Let's be direct about this: the confident numbers you'll find for mots c half life, motsc half life, or 'MOTS-c t1/2' are almost entirely copied from each other rather than from any study. That's not a conspiracy, it's citation drift. One page guessed, the next quoted it, and within a few years the guess acquired the appearance of consensus. The intellectually honest answer is that structural pharmacology predicts rapid clearance for an unmodified 2 kDa peptide, and that the definitive human figure has not yet been published. A hedged true statement beats a precise invented one every time.
Researchers working with this compound can review batch identity and purity documentation in our certificates of analysis library, read the broader compound background on our MOTS-c research page, or compare presentations between MOTS-c 10mg lyophilised vials and the MOTS-c liquid spray format. The wider research peptide catalog follows the same small-batch synthesis and third-party testing standard, and lab and ordering details are listed on our locations page.
The mots c half life question turns out to be a useful test of how a field handles its own gaps. A peptide can be characterised well enough for a decade of mechanistic publications and still have no validated pharmacokinetic profile, because those are two different research programmes funded by two different kinds of interest. If a number matters to your study design, the only defensible path is to generate it yourself with a labelled tracer and a validated assay, then publish the method alongside it. Everything else is a rumour with decimal places.
References
Peer-reviewed sources on MOTS-c indexed in PubMed, listed for research context. Real Peptides supplies MOTS-c for laboratory research use only.
- MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free radical biology & medicine, 2026. PMID 41520850. doi:10.1016/j.freeradbiomed.2026.01.002
- Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction. Biomedicines, 2026. PMID 42193373. doi:10.3390/biomedicines14051048
- MOTS-c, a mitochondrial-derived peptide, ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation. Autophagy, 2026. PMID 42153537. doi:10.1080/15548627.2026.2677180
- Mitochondrial-derived peptide MOTS-c targets SLC7A11 to preserve spermatogenesis by suppressing ferroptosis. Free radical biology & medicine, 2026. PMID 41933740. doi:10.1016/j.freeradbiomed.2026.03.074
- MOTS-c attenuates cardiac dysfunction following high altitude exposure by promoting mitophagy. Free radical biology & medicine, 2026. PMID 41654147. doi:10.1016/j.freeradbiomed.2026.01.064
- Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes. Experimental & molecular medicine, 2025. PMID 40855115. doi:10.1038/s12276-025-01521-1
- MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free radical biology & medicine, 2025. PMID 41043625. doi:10.1016/j.freeradbiomed.2025.09.056
- MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. American journal of respiratory cell and molecular biology, 2025. PMID 40035775. doi:10.1165/rcmb.2024-0533OC
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add doses.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA